DT120 ODT Phase 3 Study Succeeds in Major Depressive Disorder, Meeting All Endpoints
DFTX has more than doubled off its 52-week low of $6.345.
Summary
Definium Therapeutics announced positive topline results from its Phase 3 EMERGE study of DT120 ODT for Major Depressive Disorder. The drug met all primary and key secondary efficacy endpoints and was generally well tolerated with no serious adverse events. This follows earlier disclosures in April and May detailing upcoming Phase 3 data readouts for DT120. Successful Phase 3 results are a critical step towards regulatory approval and commercialization, significantly de-risking the development program for this drug candidate.
At the time of this announcement, DFTX was trading at $34.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $6.35 to $26.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.